<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) prognosis and survival are strictly related to the development of distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>New targeted therapies have increased patient survival, but the objective response rate is still very limited, partially because of a traditional focus on designing treatment according to the molecular profile of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> regardless the diversity between the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The objective of this study was to evaluate the presence of molecular <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> during metastatic progression and its potential impact on clinical treatment </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The authors analyzed v-Ki-ras2 Kirsten rat <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homolog (KRAS) codon 12 mutations, the v-Raf murine <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homolog B1 (BRAF) <z:chebi fb="2" ids="17821">thymine</z:chebi> to <z:chebi fb="1" ids="16708">adenine</z:chebi> substitution at codon 1788, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> protein 53 (p53) mutations and investigated promoter methylation of Ras association (RalGDS/AF-6) domain family member 1 protein (RASSF1a), E-cadherin, and cyclin-dependent kinase inhibitor 2A (p16INK4a) in 101 primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> (67 stage III and 34 stage IV) and related lymph node and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">Lymph node metastases</z:e> were characterized by fewer alterations compared with <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e>, especially KRAS (P = .03) and p16INK4a (P = .05) </plain></SENT>
<SENT sid="5" pm="."><plain>Genetic changes, when detectable in <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, mostly were retained from the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e>, whereas epigenetic changes more frequently were acquired de novo </plain></SENT>
<SENT sid="6" pm="."><plain>Overall, 31 distinct <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> molecular profiles were detected, none of which characterized a particular <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage </plain></SENT>
<SENT sid="7" pm="."><plain>When the metastatic lesions also were included in the profiles, there were 53 distinct molecular profiles in 67 patients with stage III disease and 34 distinct molecular profiles in 34 patients with stage IV disease </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Lymph node and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> appear to originate in clonally different processes, with more molecular alterations occurring in distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> than in <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> and with elevated <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, potential prognostic targets should be carefully evaluated for their <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in both <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> to avoid erroneous misclassification </plain></SENT>
</text></document>